Fortress Biotech CEO and leadership

A world-renowned physician and entrepreneur, Lindsay Rosenwald has served the medical profession for over 30 years. In that time, Lindsay Rosenwald has achieved success in a wide array of services including venture capital, direct investing, asset management and investment banking within the field of life sciences and biotechnology.

Most notably, Lindsay Rosenwald has been a significant creator of development-stage biotechnology companies. Throughout his professional career, Lindsay Rosenwald has overseen the development of more than 100 licensed clinical-stage medicines. A number of these drugs have earned approval from the U.S. Food and Drug Administration and foreign countries. One medicine in particular was to treat acute promyelocytic leukemia, which has since cured several thousands of incurable patients in the past decade. Under the guidance of Lindsay Rosenwald, the medicine has marked a dramatic shift in how the disease will be treated in the future.

Another cancer medicine formulated under the leadership of Lindsay Rosenwald is a prostate cancer drug called abiraterone acetate. The company led by Lindsay Rosenwald that developed this drug became the first of its kind to be acquired for around $1 billion after the completion of just a single phase 2 study when Johnson & Johnson took ownership of the company in a short-term merger. Other drugs approved during the career of Lindsay Rosenwald include drugs approved for treatment of diseases such as schizophrenia, influenza, fibromyalgia, infant respiratory distress syndrome, and obesity.

After graduating from southeast Pennsylvania’s Abington Senior High School in 1973, Lindsay Rosenwald matriculated at Pennsylvania State University. There, Lindsay Rosenwald received a bachelor’s degree in finance and economics, graduating a member of Beta Gamma Sigma, an international honor society.

Robyn Hunter is a Vice President & Corporate Controller at Coronado Biosciences; CFO/Secretary/Treasurer at FORTRESS BIOTECH, INC.; and Secretary at MUSTANG BIO, INC. and is based in Boston, Massachusetts. She has worked as Staff Accountant at Automatix Inc, Controller at Indevus Pharmaceuticals, and Accounting Operations Supervisor at AZUL HOLDINGS INC. Robyn works or has worked at Pricewaterhousecoopers LLP. She studied at Union College between 1979 and 1983.

A world-renowned physician and entrepreneur, Lindsay Rosenwald has served the medical profession for over 30 years. In that time, Lindsay Rosenwald has achieved success in a wide array of services including venture capital, direct investing, asset management and investment banking within the field of life sciences and biotechnology.

Most notably, Lindsay Rosenwald has been a significant creator of development-stage biotechnology companies. Throughout his professional career, Lindsay Rosenwald has overseen the development of more than 100 licensed clinical-stage medicines. A number of these drugs have earned approval from the U.S. Food and Drug Administration and foreign countries. One medicine in particular was to treat acute promyelocytic leukemia, which has since cured several thousands of incurable patients in the past decade. Under the guidance of Lindsay Rosenwald, the medicine has marked a dramatic shift in how the disease will be treated in the future.

Another cancer medicine formulated under the leadership of Lindsay Rosenwald is a prostate cancer drug called abiraterone acetate. The company led by Lindsay Rosenwald that developed this drug became the first of its kind to be acquired for around $1 billion after the completion of just a single phase 2 study when Johnson & Johnson took ownership of the company in a short-term merger. Other drugs approved during the career of Lindsay Rosenwald include drugs approved for treatment of diseases such as schizophrenia, influenza, fibromyalgia, infant respiratory distress syndrome, and obesity.

After graduating from southeast Pennsylvania’s Abington Senior High School in 1973, Lindsay Rosenwald matriculated at Pennsylvania State University. There, Lindsay Rosenwald received a bachelor’s degree in finance and economics, graduating a member of Beta Gamma Sigma, an international honor society.

A world-renowned physician and entrepreneur, Lindsay Rosenwald has served the medical profession for over 30 years. In that time, Lindsay Rosenwald has achieved success in a wide array of services including venture capital, direct investing, asset management and investment banking within the field of life sciences and biotechnology.

Most notably, Lindsay Rosenwald has been a significant creator of development-stage biotechnology companies. Throughout his professional career, Lindsay Rosenwald has overseen the development of more than 100 licensed clinical-stage medicines. A number of these drugs have earned approval from the U.S. Food and Drug Administration and foreign countries. One medicine in particular was to treat acute promyelocytic leukemia, which has since cured several thousands of incurable patients in the past decade. Under the guidance of Lindsay Rosenwald, the medicine has marked a dramatic shift in how the disease will be treated in the future.

Another cancer medicine formulated under the leadership of Lindsay Rosenwald is a prostate cancer drug called abiraterone acetate. The company led by Lindsay Rosenwald that developed this drug became the first of its kind to be acquired for around $1 billion after the completion of just a single phase 2 study when Johnson & Johnson took ownership of the company in a short-term merger. Other drugs approved during the career of Lindsay Rosenwald include drugs approved for treatment of diseases such as schizophrenia, influenza, fibromyalgia, infant respiratory distress syndrome, and obesity.

After graduating from southeast Pennsylvania’s Abington Senior High School in 1973, Lindsay Rosenwald matriculated at Pennsylvania State University. There, Lindsay Rosenwald received a bachelor’s degree in finance and economics, graduating a member of Beta Gamma Sigma, an international honor society.